Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACIP In Brief

Executive Summary

Merck Rotateq pricing: CDC estimates the cost-effective ceiling for a three-dose vaccination series of Merck's pending rotavirus vaccine is $67, the agency reported to its Advisory Committee on Immunization Practices Oct. 27. Merck has not set a price for the vaccine, but said it is committed to a level that will assure widespread use and availability. CDC predicts cost-effectiveness of a routine vaccination schedule for Rotateq would be in the same range as Sanofi-Aventis' meningococcal vaccine Menactra. ACIP's rotavirus vaccine working group is recommending universal administration of three doses of the vaccine at two, four and six months of age. Merck expects approval of Rotateq in early 2006. GlaxoSmithKline said it is in discussions with FDA about licensing its rotavirus vaccine Rotarix in the U.S...

You may also be interested in...



Merck RotaTeq Approval Will Bring Spring Shower Of Disease Awareness Ads

Merck will begin a targeted disease awareness print and internet advertising campaign this spring as part of the launch of the rotavirus vaccine RotaTeq

Merck RotaTeq Approval Will Bring Spring Shower Of Disease Awareness Ads

Merck will begin a targeted disease awareness print and internet advertising campaign this spring as part of the launch of the rotavirus vaccine RotaTeq

Gardasil Review: Will HPV Vaccine Be Inoculated Against Plan B Politics?

HHS regulatory decisions on human papilloma virus vaccines will likely face heightened scrutiny following revelations about FDA's decision-making process on the Rx-to-OTC switch application for Plan B

Related Content

Topics

UsernamePublicRestriction

Register

PS046534

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel